Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients

International Journal of DermatologyVolume 52, Issue 3 p. 358-362 Case report Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients Magalys Vitiello MD, Magalys Vitiello MD Florida Academic Dermatology Center, University of Miami Hospital, MiamiSearch for more papers by this authorAntonella Tosti MD, Antonella Tosti MD Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USASearch for more papers by this authorAdriana Abuchar MD, Adriana Abuchar MD Florida Academic Dermatology Center, University of Miami Hospital, MiamiSearch for more papers by this authorMartin Zaiac MD, Martin Zaiac MD Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USASearch for more papers by this authorFrancisco A. Kerdel BSc, MBBS, Francisco A. Kerdel BSc, MBBS Florida Academic Dermatology Center, University of Miami Hospital, Miami Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USASearch for more papers by this author Magalys Vitiello MD, Magalys Vitiello MD Florida Academic Dermatology Center, University of Miami Hospital, MiamiSearch for more papers by this authorAntonella Tosti MD, Antonella Tosti MD Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USASearch for more papers by this authorAdriana Abuchar MD, Adriana Abuchar MD Florida Academic Dermatology Center, University of Miami Hospital, MiamiSearch for more papers by this authorMartin Zaiac MD, Martin Zaiac MD Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USASearch for more papers by this authorFrancisco A. Kerdel BSc, MBBS, Francisco A. Kerdel BSc, MBBS Florida Academic Dermatology Center, University of Miami Hospital, Miami Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USASearch for more papers by this author First published: 20 January 2013 https://doi.org/10.1111/j.1365-4632.2011.05320.xCitations: 22 Francisco A. Kerdel, BSc, MBBSFlorida Academic Dermatology Center Director of Dermatology Inpatient Service University of Miami Hospital 1400 N.W. 12th Ave, Ste. 4 Miami, FL 33136 USA E-mail: [email protected] Funding: None. Conflict of interest: Dr Kerdel has received grants, participated in advisory boards and is speaker for: Abbott, Amgen, Wyeth, Astellas, Centocor, Genentech, Stiefel, Eisai, Merck and Novartis. Drs Vitiello, Tosti, Abuchar and Zaiac do not have any conflict of interest to disclose. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg2009; 13: 102–106. 2Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol2009; 145: 269–271. 3Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol2007; 34: 123–129. 4Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet2009; 373: 633–640. 5Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis2010; 69: 394–399. 6Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol2010; 24: 530–534. 7Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol2009; 23: 896–904. 8Korver JEM, Langewouters AMG, Van De Kerkhof PCM, Pash MC. Therapeutic effects of a 12 week course of Alefacept on nail psoriasis. J Eur Acad Dermatol Venereol2006; 20: 1252–1255. 9Rich P, Griffiths CEM, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol2008; 58: 224–231. 10Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet2005; 366: 1367–1374. 11Noiles K, Vender R. Nail psoriasis and biologics. Review. J Cutan Med Surg2009; 13: 1–5. Citing Literature Volume52, Issue3March 2013Pages 358-362 ReferencesRelatedInformation